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Predictors of Cancer-Related Cognitive Impairment in
Patients with Breast Cancer Receiving Chemotherapy
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STUDY OBJECTIVE Dehydroepiandrosterone (DHEA) and its sulfated form (DHEAS)—jointly referred to
as DHEA(S)—are neurosteroids known to regulate brain development and function that have been
found to be positively correlated with cognitive function. It is unknown whether prechemotherapy
plasma DHEA(S) levels are associated with the onset of cancer-related cognitive impairment (CRCI).
The objective of this study was to evaluate whether an association exists between prechemotherapy
plasma DHEA(S) levels and onset of CRCI in patients with breast cancer receiving chemotherapy.
DESIGN Multicenter, prospective cohort study.
SETTING Two specialized cancer centers in Singapore.
PATIENTS Eighty-one patients with early-stage breast cancer (stages I–III) who had no prior exposure
to chemotherapy and/or radiotherapy and were scheduled to receive anthracycline-based or taxane-
based chemotherapy treatment with curative intent.
MEASUREMENTS AND MAIN RESULTS Patients completed assessments for self-perceived and objective cog-
nitive function at three time points: prechemotherapy (T1), during chemotherapy (T2), and after
chemotherapy (T3). Plasma samples were collected prior to chemotherapy, and DHEA(S) levels
were quantified by using ultra–high-performance liquid chromatography–tandem mass spectrome-
try. Multivariable logistic regression was used to adjust for clinically important factors and to
evaluate the association between prechemotherapy plasma DHEA(S) levels and CRCI. Mean  SD
age was 48.9  9.3 years, with 27.8% of patients experiencing clinically significant cognitive
impairment based on global Functional Assessment of Cancer Therapy–Cognitive Function
scores. The mean  SD prechemotherapy plasma DHEAS and DHEA levels were
1.61  0.91 lmol/L and 19.21  13.13 nmol/L, respectively. Prechemotherapy DHEAS levels
were found to be associated with impairment in the self-perceived cognitive domains of verbal
fluency (adjusted odds ratio [OR] 0.27, 95% confidence interval [CI] 0.08–0.96) and mental
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acuity (adjusted OR 0.25, 95% CI 0.08–0.74). Conversely, DHEA levels were not associated with
impairment in any cognitive subdomains.
CONCLUSION Our findings suggest that patients with higher prechemotherapy DHEAS levels had lower
odds of developing self-perceived cognitive impairment. Future studies are required to further inves-
tigate the effect of DHEA(S) on specific cognitive domains and to validate our findings in indepen-
dent cohorts.
KEY WORDS oncology, quality of life, chemotherapy, dehydroepiandrosterone, cancer-related cognitive
impairment.
(Pharmacotherapy 2019;39(5):553–563) doi: 10.1002/phar.2259
Although cancer has become more curable,
with the use of chemotherapy leading to
improved survival rates, many cancer survivors
experience posttreatment adverse effects.1, 2 Of
these adverse effects, cancer-related cognitive
impairment (CRCI) is an area of clinical concern
that has been found to affect patients diagnosed
with non–central nervous system cancer. CRCI
is characterized as changes to mainly the cogni-
tive domains of memory, processing speed, and
executive function.3 In our previous studies, we
observed postchemotherapy cognitive impair-
ment in up to 37% of patients with breast can-
cer,4 and the effect persists in up to 30% of
patients for as long as up to 15 months after
treatment.5 Although the effects of CRCI may be
transient or long term, cognitive changes can
cause profound and negative impact on quality
of life in patients with cancer.6
Given the extent of the impact of CRCI, there
is a need to enhance our understanding of its
underlying biological mechanisms. This will
allow us to develop appropriate pharmacologic
interventions, which are currently limited.7
There have been several proposed mechanisms
of CRCI including, but not limited to, oxidative
stress, dysregulation of inflammatory cytokines,
genetic susceptibility, hormone deficiencies, and/
or psychological distress,8, 9 although the cause
of CRCI is likely to be multifactorial.
Dehydroepiandrosterone (DHEA) and its sul-
fated form (DHEAS)—jointly referred as DHEA
(S)—are neurosteroids that serve important
functions that help to regulate brain develop-
ment, function, and behavior. DHEA(S) are pur-
ported to exert a cognitive-preserving effect
through their neuroprotective, antioxidant, anti-
inflammatory, and antiglucocorticoid actions.10
This is mediated by binding to brain receptors
(such as the N-methyl D-aspartate and c-amino-
butyric acid receptors) for which they have
shown affinity or through the conversion into
active metabolites or more potent steroid
hormones such as estradiol.11 Although DHEA
and DHEAS can be reversibly converted into
each other, their molecular effects are not the
same, and it is postulated that the balance
between both forms influence brain function-
ing.12
In the literature, several studies have identified
associations between baseline DHEA(S) levels and
cognitive function, although the direction of the
association may differ depending on the popula-
tion studied and the measures used. In an epi-
demiologic cohort study, older women with
higher plasma DHEA(S) levels were found to be
at increased odds of reporting subjective cognitive
concerns,13 whereas in patients with bipolar dis-
order, serum DHEAS levels were found to be
inversely correlated with verbal memory.14 In
contrast, male cancer survivors with lower
DHEAS levels were found to perform worse on
the attention measure in a cross-sectional study.15
In population studies comprising the elderly,
lower DHEA(S) level were associated with a
higher prevalence of cognitive disorders in elderly
patients diagnosed with Alzheimer’s disease and
depression,16 and baseline serum DHEAS levels
remained positively associated with cognitive
function during a 3-year follow-up period.17
From these studies, we hypothesized that lower
DHEA(S) levels would be associated with poorer
cognitive function in cancer survivors, given that
they might be subjected to greater risk for cancer
treatment-related neurotoxicity.
The biological activity of DHEA(S) coupled
with their association with cognitive function
observed across various clinical populations lead
us to suggest that DHEA(S) supplementation may
potentially serve as a pharmacologic intervention
to help with cognition in CRCI. Reports of DHEA
(S) administration typically outline beneficial
effects on cognition overall, with a certain
specificity for working memory and
attention,12, 18 which may support the use of
DHEA(S) supplementation as a preemptive
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intervention to address CRCI. To support this
statement, it would be prudent to know whether
patients experiencing CRCI possess low levels of
DHEA(S) prior to chemotherapy treatment.
Hence, the main objective of our study was to
evaluate whether a relationship exists between
prechemotherapy plasma DHEA(S) levels and
CRCI in a cohort of patients with early-stage
breast cancer. If we can identify the characteris-
tics of the patients who experienced CRCI with
low baseline DHEA(S) levels, we can focus on
this specific subgroup of patients for monitoring
CRCI and tailor our intervention of DHEA(S)
supplementation accordingly.
Methods
Study Design
This was a multicenter, prospective cohort
study conducted in National Cancer Centre Sin-
gapore and KK Women’s and Children’s Hospital
between 2011 and 2016. This study was
approved by the Singhealth Institutional Review
Board (IRB 2011/457/B), and written informed
consent was obtained from all study patients.
The inclusion criteria were as follows: diag-
nosed with early-stage breast cancer (stages I–
III), had no prior exposure to chemotherapy
and/or radiotherapy, scheduled to receive
anthracycline-based or taxane-based chemother-
apy treatment with curative intent, capable of
providing informed consent, and understood
either English or Chinese. Patients were
excluded if they were diagnosed with neurologic
or psychiatric medical conditions.
All study patients were assessed at three time
points: before treatment initiation (baseline; T1),
during chemotherapy, at least 6 weeks after
baseline (T2), and after completion of
chemotherapy, at least 12 weeks after baseline,
(T3). Prior to chemotherapy initiation, each
patient’s demographic and clinical data were col-
lected and verified through patient interviews
and electronic medical records.
Study Tools
At each time point (T1, T2, and T3), patients
completed a series of questionnaires to assess
their cognitive function, behavioral symptoms,
and quality of life. All assessments were admin-
istered by trained bilingual research assistants in
either English or Chinese and took approxi-
mately 40 minutes to complete.
For self-perceived cognitive function, the Func-
tional Assessment of Cancer Therapy–Cognitive
Function (FACT-Cog) Version 3 is a validated
questionnaire used to assess the impact on the
patient’s quality of life within the past 7 days.19
Items in the subscale were organized into the
respective subdomains of mental acuity, concentra-
tion, memory, verbal fluency, functional interfer-
ence, and multitasking.20 The responses were
reverse-scored in which higher scores indicated
better self-perceived cognitive function. Patients
were defined as having self-perceived cognitive
impairment at each time point if there was a reduc-
tion of 10.6 on the global FACT-Cog score relative
to baseline (T2-T1 or T3-T1), based on the mini-
mal clinically important difference (MCID) deter-
mined in patients with breast cancer.21 For each of
the cognitive subdomain, a reduction of 15% in
scores from baseline is considered as self-perceived
cognitive impairment. This was determined a pri-
ori, based on the method of approach from other
studies that have used FACT-Cog to evaluate per-
ceived cognitive function.4, 5
For objective cognitive function, a computer-
ized neuropsychological test, Headminder, was
used to assess four domains: processing speed,
response time, memory, and attention.22 In this
study, patients were defined as having cognitive
impairment at each time point for each cognitive
domain if the Reliable Change Index (RCI) was
lower than 1.5 relative to baseline (T2-T1 or
T3-T1).3 The RCI accounted for practice effect
and measurement error by considering the
repeated normative mean and standard error of
the difference.22
At each time point, the self-administered Brief
Fatigue Inventory (BFI), Beck Anxiety Inventory
(BAI), and the European Organization for Research
and Treatment of Cancer Quality of Life Question-
naire (EORTC QLQ-C30) were also used to cap-
ture patients’ fatigue symptoms, anxiety symptoms,
and health-related quality of life, respectively. The
symptom scale of the EORTC was used to assess
for insomnia in our patient cohort.
Quantification of Prechemotherapy Plasma
DHEA(S) Levels
Prior to initiation of chemotherapy, blood
(10 ml) was collected from each patient and
stored in ethylenediaminetetraacetic acid tubes.
The blood sample was centrifuged at 1069 9 g
for 30 minutes, and the plasma sample was
stored in a 80°C freezer until sample analysis.
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Ultra–high-performance liquid chromatography–
tandem mass spectrometry (UPLC-MS/MS)
methods were developed and quantitatively vali-
dated for specificity, linearity, lower limit of
quantification (LLOQ), accuracy and precision,
matrix effect, and extraction recovery in accor-
dance with the United States Food and Drug
Administration’s Bioanalytical Method Validation
(May 2018)23 for the quantification of DHEA(S)
levels in patient plasma (Table S1).
The samples prepared were assayed using an in-
house developed UPLC-MS/MS methodology. An
Agilent C18 column (2.1 9 50 mm, 1.8 lm) (Agi-
lent Technologies, Santa Clara, CA) was used in
tandem with an AB Sciex 3500 triple quadrupole
mass spectrometer (Applied Biosystems, Foster
City, CA). Negative electrospray ionization (ESI)
with multiple reaction monitoring mode was used
to quantify DHEAS (367.0 ? 97.0) whereas the
positive ESI mode was used for DHEA
(289.1 ? 253.6) in their respective mass/charge
ratios (m/z). Internal standards of estrone 3-sulfate-
d5 sodium salt (354.2 ? 274.0) and cortisol-d4
(367.2 ? 121.0) were used for DHEAS and
DHEA, respectively. DHEA(S) levels were then
determined by using Version 1.4.2 of Analyst
Software (Applied Biosystems). The mobile phase
consisted of (A) 10 mM ammonium acetate and
(B) acetonitrile for DHEAS, and (A) 0.1% formic
acid and (B) 0.1% formic acid in acetonitrile for
DHEA.
Statistical Analysis
Descriptive statistics were used to summarize
patients’ demographic and clinical characteristics.
The number of patients with CRCI relative to
baseline (T2-T1 or T3-T1) was described as pro-
portions. An independent t test was used for sub-
group analyses to compare DHEA(S) levels
between patients who were cognitively impaired
and nonimpaired, defined by the respective sub-
domains. Multivariable logistic regression was
used to evaluate the association between
prechemotherapy DHEA(S) levels and CRCI, with
results reported as odd ratios (ORs) with 95%
confidence intervals (CIs). Clinically important
factors that may influence cognitive function,
including age,24 years of education,25 fatigue at
baseline,26 anxiety at baseline,27 insomnia at base-
line,28 planned chemotherapy regimen,29 and
menopausal status,30 were adjusted for in the final
model. All statistical analyses were performed
with STATA version 15 (2017) (StataCorp, Col-
lege Station, TX), and two-sided p values less than
0.05 were considered to indicate a statistically sig-
nificant difference.
Results
Patient Characteristics
A total of 81 patients were included in the
analysis (Figure 1), and their baseline demo-
graphic and clinical characteristics are summa-
rized in Table 1. Mean  SD age and years of
education of the patients were 48.9  9.3 and
11.0  3.4 years, respectively. The patients were
predominantly Chinese (82.7%), had stage II
breast cancer (54.3%), and had excellent perfor-
mance status (ECOG = 0, 91.4%). More than
half of the patients were receiving an anthracy-
cline-based chemotherapy regimen (66.7%) and
were premenopausal (53.1%).
Overall Rate of Self-Perceived and Objective
CRCI
The mean  SD for global FACT-Cog scores
across the various time points were as follows:
116.7  15.0 (T1), 118.2  14.2 (T2), and
114.0  15.0 (T3). (Figure S1) Based on global
FACT-Cog scores, 13.8% and 21.5% of patients
reported self-perceived cognitive impairment at
T2 and T3, respectively. The overall percentage
of patients experiencing self-perceived cognitive
impairment over the study period was 27.8%
(Table 2). For self-perceived cognitive impair-
ment, the proportion of patients (n=79)
impaired in mental acuity (24.1%), concentra-
tion (21.5%), memory (13.9%), verbal fluency
(12.7%), functional interference (13.9%) and
multitasking (26.6%) cognitive domains are as
listed respectively. With regard to objective cog-
nitive impairment with the assessments con-
ducted using Headminder, the proportion of
patients (n=71) impaired in memory (21.1%),
attention (12.7%), processing speed (7.0%), and
response speed (5.6%) are as listed respectively.
Comparison of Prechemotherapy DHEA(S)
Levels across Respective Cognitive Subdomains
The mean  SD plasma DHEAS and DHEA
levels were reported to be 1.61  0.91 lmol/L
and 19.21  13.13 nmol/L, respectively. DHEA
(S) levels were compared and analyzed across
the various cognitive subdomains (Table 3). In
the domain of verbal fluency, DHEAS levels
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were significantly lower in the cognitively
impaired group compared with the non–cogni-
tively impaired group (0.98  0.43 lmol/L vs
1.70  0.94 lmol/L, p=0.02) (Figure 2). Lower
DHEAS levels were observed in patients with
cognitive impairment for majority of the identi-
fied cognitive subdomains except for the domain
of attention. Similarly, lower absolute plasma
DHEA levels were also observed in cognitively
impaired patients defined by mental acuity, con-
centration, verbal fluency, multitasking, and
objective domains of processing speed. However,
no statistically significant differences between
the two groups were found.
Association between Prechemotherapy DHEA(S)
Levels and Clinically Relevant Factors and CRCI
In terms of self-perceived cognitive impair-
ment, DHEAS level was associated with the
domain of verbal fluency (OR 0.29, 95% CI
0.09–0.88). DHEA was not associated with any
self-perceived cognitive domains (both unad-
justed and adjusted ORs), with its ORs being
mostly close to 1 (Table 4). After adjusting for
age, years of education, fatigue level, anxiety
level, insomnia, type of chemotherapy regimen,
and menopausal status, the association between
prechemotherapy plasma DHEAS levels and ver-
bal fluency was retained (adjusted OR 0.27, 95%
CI 0.08–0.96). This adjusted OR of 0.27 meant
that for every unit increase in prechemotherapy
plasma DHEAS level (lmol/L), there was a 73%
less risk of being cognitively impaired defined
by verbal fluency during the period of
chemotherapy, after adjusting for the listed con-
founders. In addition, DHEAS level was associ-
ated with impairment in the self-perceived
cognitive domain of mental acuity (adjusted OR
0.25, 95% CI = 0.08–0.74) after adjusting for
confounders.
There were no statistically significant associa-
tion between DHEA(S) levels and impairment in
the objective cognitive measures of processing
speed, response speed, memory, and attention. In
the univariate analysis, age, fatigue, and anxiety
levels were found to be significantly associated
with objective cognitive impairment (Table S2).
Total participants recruited (n=117) 
Did not provide plasma  
sample at T1 (n=36) 
Analyzed for self-perceived cognitive 
impairment (n=79) 
Excluded from analysis (n=2): 
Missing FACT-Cog scores at T1 (n=1) 
Missing FACT-Cog scores at T2 (n=0) 
Missing FACT-Cog scores at T3 (n=1) 
Analyzed for objective cognitive impairment (n=71) 
Excluded from analysis (n=10): 
Missing Headminder scores at T1 (n=1) 
Missing Headminder scores at T2 (n=3) 
Missing Headminder scores at T3 (n=2) 
Missing Headminder scores at T1 & T2 (n=1) 
Missing Headminder scores at T2 & T3 (n=1) 
Missing Headminder scores at T1, T2, & T3 
(n=2) 
Analysis 
Participants included in analysis (n=81) 
Enrollment
Figure 1. Flow diagram of the patient selection process. FACT-Cog = Functional Assessment of Cancer Therapy–Cognitive
Function.
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With respect to predictors of onset of objective
cognitive impairment, older age was found to be
associated with higher odds of developing CRCI
in the domain of attention (OR 1.10, 95% CI
1.00–1.21), whereas greater fatigue levels and anx-
iety levels were found to be associated with
domain of response speed (OR 1.77, 95% CI 1.02–
3.07, and OR 1.13, 95% CI 1.00–1.29, respec-
tively). In contrast, none of the confounders were
found to be statistically significant in impairment
in the self-perceived cognitive domains.
Discussion
This study aimed to investigate the association
between prechemotherapy plasma DHEA(S)
levels with CRCI, with our hypothesis being that
lower DHEA(S) levels would be associated with
poorer cognitive function. Consistent with our
hypothesis, higher prechemotherapy DHEAS
levels were reported to be associated with lower
odds of developing cognitive impairment in the
self-perceived domains of verbal fluency (ad-
justed OR 0.27, 95% CI 0.08–0.96) and mental
acuity (adjusted OR 0.25, 95% CI 0.08–0.74)
after adjusting for confounders. The association
observed with verbal fluency is corroborated
by findings from a review that identified verbal
fluency, working memory, and attention as
domains with which DHEAS showed positive
correlation.18 However, we did not observe
Table 1. Baseline Demographic and Clinical Characteris-
tics of the Study Patients
Characteristic Data (n=81)
Age (yrs) 48.9  9.3
Years of education 11.0  3.4
DHEAS level (lmol/L) 1.61  0.91
DHEA level (nmol/L) 19.21  13.13
Fatigue level scorea 1.76  1.69
Anxiety level scoreb 7.27  6.38
Insomnia scorec 20.25  25.82
Ethnicity
Chinese 67 (82.7)
Malay 9 (11.1)
Indian 2 (2.5)
Other 3 (3.7)
Breast cancer stage
I 14 (17.3)
II 44 (54.3)
III 23 (28.4)
ECOG performance status
0 74 (91.4)
1 7 (8.6)
Chemotherapy regimen
Anthracycline based 54 (66.7)
Taxane based 27 (33.3)
Menopausal status
Premenopausal 43 (53.1)
Postmenopausal 38 (46.9)
Data are mean  SD values or no. (%) of patients.
DHEA = dehydroepiandrosterone; DHEAS = DHEA sulfate;
ECOG = Eastern Cooperative Oncology Group.
aThe Brief Fatigue Inventory’s total score is out of a maximum of
10 points, with a higher score indicating more severe fatigue.
bThe Beck Anxiety Inventory’s total score is out of a maximum of
63 points, with a higher score indicating more severe anxiety.
cThe insomnia’s subscale total score is out of a maximum of 100
points, with a higher score indicating more or worse symptoms.
Table 2. Frequency of Self-Perceived and Objective Cancer-Related Cognitive Impairment
No. (%) of Patientsa
T2-T1 T3-T1 Overall
Self-perceived cognitive function, FACT-Cog Domainsb (n=80) (n=79) (n=79)
Total FACT-Cog score 11 (13.8) 17 (21.5) 22 (27.8)
Mental acuity 11 (13.8) 15 (19.0) 19 (24.1)
Concentration 10 (12.5) 12 (15.2) 17 (21.5)
Memory 6 (7.5) 9 (11.4) 11 (13.9)
Verbal fluency 5 (6.3) 7 (8.9) 10 (12.7)
Functional Interference 4 (5.0) 7 (8.9) 11 (13.9)
Multitasking 12 (15.0) 15 (19.0) 21 (26.6)
Objective cognitive function, Headminder domainsc (n=78) (n=78) (n=71)
Processing speed 2 (2.6) 4 (5.2) 5 (7.0)
Response speed 2 (2.6) 2 (2.6) 4 (5.6)
Memory 7 (9.0) 13 (16.7) 15 (21.1)
Attention 8 (6.0) 4 (5.2) 9 (12.7)
FACT-Cog = Functional Assessment of Cancer Therapy–Cognitive Function.
aPatients were excluded from the analysis for a particular domain if they had missing measures at T1 and/or the measured time point (T2 or
T3, respectively).
bSelf-perceived cognitive impairment was defined as any decrease in FACT-Cog global score of 10.6 points or more, whereas self-perceived
cognitive impairment in specific domains was defined as any 15% decrease from baseline scores.
cObjective cognitive impairment was defined as a reliable change index score < 1.5 compared with baseline in the particular Headminder
domain.
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higher DHEAS levels being favorably associated
with executive function, concentration, and
working memory in our cohort, which were
domains identified in a community-based study
conducted in women.31 More studies are
required to further investigate the effect of
DHEAS level on specific cognitive domains.
Conversely, prechemotherapy DHEA levels do
not predict for onset of CRCI given how their
reported ORs were mostly close to 1, which
translated to a little or no change in cognitive
status per unit increase in prechemotherapy
plasma levels. There does not seem to be a
major role contributed by DHEA(S) level in
pathways related to objective cognitive impair-
ment, with none of the associations being identi-
fied as statistically significant.
In terms of clinically relevant factors, age, fati-
gue level, and anxiety level were found to be
related to onset of objective CRCI in our cohort.
This finding is congruent with a review that
identified that risk factors for CRCI included
cognitive reserve, age, genetic factors, and eth-
nicity1 and a study that reported that older age
was associated with a higher odds of developing
CRCI in the domain of attention.32 There are
also findings that suggest lower baseline serum
DHEAS levels being associated with physical
frailty and related adverse health outcomes in
the elderly.33 In another study assessing clinical
factors that correlate with baseline cognitive
function of patients with breast cancer, age was
similarly identified to be a predictor, with up to
40% of elderly patients with breast cancer pre-
senting with cognitive deficits even before any
adjuvant therapy.34 In addition, anxiety, depres-
sion, and fatigue levels were also found to be
correlated with cognitive complaint scores. It
should be noted that most studies that observed
positive associations between plasma DHEA(S)
levels and cognition were conducted in the
elderly population, and this correlation could
have been possibly mediated by age-related
decline of plasma DHEA(S) levels. These studies
in the elderly have found a positive association
with plasma DHEAS levels, with the listed
domains of functional interference,35, 36 process-
ing speed,37 and memory.18
There could be several possible reasons to
explain why there was a lack of association
observed between DHEA levels and other cogni-
tive subdomains. Although DHEA(S) are related
Figure 2. Box plots of mean  SD baseline plasma
dehydroepiandrosterone sulfate (DHEAS) levels for the
non–cognitively impaired and cognitively impaired groups
defined by the verbal fluency domain.
Table 4. Association between Prechemotherapy Plasma DHEAS and DHEA Levels with Onset of Cancer-Related Cognitive
Impairment during Chemotherapy
Cognitive Measure
DHEAS Level DHEA Level
OR (95% CI) Adjusted OR (95% CI)a OR (95% CI) Adjusted OR (95% CI)a
Self-perceived cognitive measure
FACT-Cog global score 0.65 (0.36–1.19) 0.48 (0.23–0.99) 1.00 (0.96–1.03) 1.00 (0.95–1.05)
Mental acuity 0.55 (0.28–1.07) 0.25 (0.08–0.74) 0.99 (0.95–1.03) 0.99 (0.94–1.06)
Concentration 0.58 (0.29–1.15) 0.45 (0.20–1.00) 0.99 (0.96–1.04) 1.00 (0.95–1.06)
Memory 0.56 (0.24–1.28) 0.64 (0.24–1.67) 1.01 (0.97–1.06) 1.02 (0.95–1.09)
Verbal fluency 0.29 (0.09–0.88) 0.27 (0.08–0.96) 0.98 (0.92–1.04) 0.97 (0.89–1.05)
Functional interference 0.59 (0.26–1.35) 0.55 (0.20–1.50) 1.00 (0.96–1.06) 1.04 (0.97–1.10)
Multitasking 0.94 (0.54–1.63) 0.89 (0.45–1.76) 0.99 (0.96–1.03) 0.98 (0.93–1.04)
Objective cognitive measure
Processing speed 0.36 (0.09–1.42) 0.15 (0.01–1.78) 0.96 (0.87–1.06) 0.90 (0.73–1.11)
Response speed 0.60 (0.17–2.17) 0.09 (0.004–2.04) 1.02 (0.96–1.08) 1.10 (0.96–1.28)
Memory 0.94 (0.50–1.77) 1.00 (0.49–2.06) 1.02 (0.97–1.06) 1.01 (0.96–1.06)
Attention 1.33 (0.64–2.76) 1.53 (0.53–4.43) 1.00 (0.96–1.06) 1.03 (0.97–1.10)
Bolded values indicate statistical significance.
CI = confidence interval; DHEA = dehydroepiandrosterone; DHEAS = DHEA sulfate; FACT-Cog = Functional Assessment of Cancer Therapy
–Cognitive Function; OR = odds ratio.
aAdjusted for age, years of education, fatigue level, anxiety level, insomnia, type of chemotherapy regimen, and menopausal status.
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along the same pathway, with each being able
to reversibly convert to the other, prechemo-
therapy plasma DHEA(S) levels have varying
influence on the onset of CRCI. This could be
related to the location of brain region affected
by CRCI, with the hippocampus being the most
likely, since decline in memory is maintained
by the prefrontal cortex and hippocampus.38
Neuroendocrinological studies have shown that
the concentrations of DHEA(S) across different
brain regions vary considerably, with DHEA
showing the highest concentration in the pre-
frontal cortex,11 and DHEAS being mostly con-
centrated at the posterior region of the brain.39
The lack of association seen for DHEA may also
be attributed to a larger variation in plasma
DHEA levels compared to DHEAS due to
DHEA’s relatively short half-life40 as well as the
diurnal41 and/or menstrual cycle variation.42
Given how levels of DHEAS may be indicative
of hypothalamic-pituitary-adrenal (HPA) axis
integrity, the greater extent of the impact
observed with DHEAS also suggests that the
dysfunction of HPA axis and/or impairment of
adrenal function may potentially contribute to
poorer neurocognitive outcomes among cancer
survivors.43 Together, the difference in pharma-
cokinetic profiles, location, and choice of med-
ium contribute as factors that could have
undermined the magnitude of association
between DHEA levels and CRCI.
Being able to establish a relationship between
prechemotherapy plasma levels of DHEAS with
impairment in specific cognitive domains would
be useful in a clinical setting. There is potential
application for the use of DHEA(S) supplemen-
tation as replacement therapy to mitigate the
impact of CRCI in subgroup of patients who
have low prechemotherapy levels to begin with,
and who might be more vulnerable to its effects.
DHEA(S) supplements are currently widely
available, but the efficacy and adverse effect pro-
file of DHEA(S) supplementation have not been
demonstrated in many clinical studies.16, 44 The
pathway-related actions may be dependent on
the type of population, be it clinical, elderly
individuals, or healthy controls. In fact, an
opposing review surmised that in studies with
DHEA supplementation, improvement in cogni-
tive function was not achieved.18 This begs the
question that the lack of biological activity of
DHEA(S) on the site of action could be attribu-
ted to poor oral bioavailability or insufficient
doses.45 DHEA is typically marketed as a dietary
supplement in doses of 25–50 mg per day but
doses up to 300 mg may be chosen for clinical
studies. Although there is general agreement that
DHEA(S) supplementation can exert beneficial
effects on mood and well-being,12, 18 robust
clinical trials need to be conducted before it can
be determined whether DHEA(S) supplementa-
tion may serve as a potential pharmacologic
intervention for CRCI.
Compared to other studies in literature inves-
tigating CRCI, our study’s strength stems from
its longitudinal nature, which allows us to dis-
cern the different trajectories of CRCI over time.
In addition, we have distinguished and evaluated
both objective and subjective assessments of cog-
nitive changes in our patient cohort. As objec-
tive assessments evaluate the patient’s cognitive
function in a controlled setting, they often fail to
consider patients’ experience with activities of
daily living and the impact on quality of
life.46, 47
This study has several limitations. First, mea-
surement of plasma DHEA(S) level may not be
indicative of actual physiologic levels in the site
of action—brain tissue. However, obtaining tis-
sue samples and cerebrospinal fluid would be
invasive and logistically challenging, and thus
plasma would present the most suited medium.
The brain-to-plasma ratios for DHEA and
DHEAS have been found to be about 4–6.5 and
8.5, respectively, with higher concentrations of
neurosteroid found in the brain, although wide
interindividual differences have also been
observed.48 Second, although DHEA supplemen-
tation may improve memory, it is unclear
whether this effect could have been mediated
through conversion of these steroids into andro-
gens or estradiol. Future work should also
account for levels of sex hormones and patients
who are taking hormonal replacement therapies
in order to demonstrate a clearer correlation
with cognition. Third, the International Cogni-
tion and Cancer Task Force recommends includ-
ing diseased and/or healthy controls in studies.3
The addition of a diseased control group—non–
chemotherapy-receiving patients with breast can-
cer—may provide more information on whether
lower DHEA(S) levels could be due to the malig-
nancy itself. Lastly, we also acknowledge the
lack of adjustment for multiple testing for each
of the specific subdomains of cognition in our
data analysis. Given the exploratory nature of
our study, our findings in relation to subdo-
mains may be considered as hypothesis generat-
ing until these findings have been validated in
independent patient cohorts.
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Conclusion
Our findings suggest that patients with higher
prechemotherapy plasma levels of DHEAS have
lower odds of developing self-perceived cogni-
tive impairment in verbal fluency and mental
acuity. Future studies are required to further
investigate the effect of DHEA(S) on specific
cognitive domains and to validate our findings
in independent cohorts. More research should
also be conducted to understand role of DHEA
(S) as predictors of cognitive function in path-
ways related to CRCI.
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